ClinicalTrials.gg
Active, not recruitingNCT04639050Updated Sep 14, 2026

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

A Phase 1/2 interventional study of RO7126209 and Placebo in Alzheimers Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 37 sites in 9 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Alzheimer Disease by Hoffmann-La Roche — 3 open to participants now, 8 under way, 4 of them phase 3. Alzheimer Disease · Hoffmann-La Roche.

Enrollment
21st of 40
241 · median 247
Started
2021
with 1 other
Phase 1/2
Only one
of the 40
Registered
32nd of 40
by date

Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one is the 21st largest by enrollment, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 32nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 40 studies in Alzheimer Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Alzheimer Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.

03

Conditions studied

  • Alzheimers Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Key inclusion criteria for part 1, 2 and 3:

  • Ability to provide written consent signed by the participant
  • Availability of a person (referred to as the "study partner") who: consents to participate throughout the duration of study, in the Investigator's judgment, has frequent and sufficient contact with the participant, is fluent in the language of the tests used at the study site
  • Willingness and ability to complete all aspects of the study (including magnetic resonance imaging [MRI], lumbar puncture, clinical genotyping, and positron emission tomography [PET] imaging)
  • Capable of completing assessments either alone or with the help of the study partner
  • Adequate visual and auditory acuity, in the Investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
  • Probable mild to moderate AD dementia (consistent with National Institute on Aging-Alzheimer's Association [NIA-AA] core clinical criteria for probable AD dementia) or prodromal AD (consistent with the NIA-AA diagnostic criteria and guidelines for mild cognitive impairment due to AD)
  • Screening (MMSE) score of 18 to 28 points, inclusive, within 84 days before baseline
  • Clinical Dementia Rating-Global Score (CDR-GS) of 0.5, 1, or 2 within 84 days before baseline
  • Positive amyloid PET scan (cut-off: >50 Centiloid units) within 12 months before baseline
  • In case of treatment with symptomatic AD medications, dosing regimen must be stable for at least 8 weeks prior to baseline and until randomization
  • Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug
  • Agreement not to participate in other research studies for the duration of this study
  • Agree to apolipoprotein E (APOE) genotyping

Inclusion criteria

Inclusion criteria for Part 4:

- Completed the treatment period in Part 1, Part 2, or Part 3 of the study

Key exclusion criteria for part 1, 2 and 3:

  • Any evidence of other relevant neurological condition, including other (non-AD) neurodegenerative and neuropsychiatric conditions, neurovascular brain disorders, seizure disorders, inflammatory and infectious disorders of the central nervous system, trauma and delirium, among several others
  • Other relevant medical conditions including significant hematological diseases, any ophthalmologic diseases, decreased visual acuity in either eye, with a BCVA letter score of less than 20 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or the Snellen equivalent of 20/400 if the ETDRS chart is not used
  • Clinically significant cardiovascular diseases, chronic kidney disease, confirmed and unexplained impaired hepatic function, abnormal thyroid function, among several others
  • History of to biologic agents or any of the in the formulation
  • Clinically significant abnormalities (as judged by the Investigator) in laboratory test results (including complete blood count, chemistry panel, routine cerebrospinal fluid [CSF] parameters and urinalysis)
  • MRI exclusion criteria: >2 lacunar infarcts (including lacunar infarcts in the cerebellum), any territorial infarct >1 cm\^3, any white matter lesion that corresponds to an overall Fazekas score of 3 that requires at least one confluent hyperintense lesion on the fluid-attenuated inversion recovery (FLAIR) sequence, which is ≥20 mm in any dimension
  • More than 4 microhemorrhages on MRI and/or presence of any focal area of hemosiderosis based on the review performed by the central MRI reader prior to randomization
  • Presence of any other significant cerebral abnormalities, including amyloid-related imaging abnormality-edema/effusion (ARIA-E), as assessed on MRI
  • Inability to tolerate MRI procedures or to MRI
  • Inability to undergo ophthalmological assessments
  • Contraindication to lumbar puncture
  • Contraindication to having a PET scan

Exclusion criteria

Exclusion criteria for Part 4:

  • Prematurely discontinued from the treatment period for study (i.e., before the start of the follow-up period of Part 1, Part 2, or Part 3) for any reason or meeting discontinuation criteria before the baseline visit of Part 4.
  • Received any active treatment other than RO7126209 during or since completion of Part 1, Part 2 or Part 3
  • Any passive immunotherapy (immunoglobulin) since completion of Part 1, Part 2, or Part 3 that is meant to prevent or postpone cognitive decline.
  • Use of anti-coagulation medications - Evidence of ongoing ARIA-E. In this case participant may enroll into Part 4 once the ARIA-E is resolved - Evidence of ongoing infusion-related reaction (IRR) or reaction. In this case participant may enroll into Part 4 once the IRR is resolved.
  • MRI evidence of any of the following at OLE baseline: evidence of ongoing ARIA-E, any ARIA-H ( hemosiderosis or microhemorrhages) that would require permanent discontinuation of study treatment, > 2 lacunar infarcts, Any territorial infarct > 1 cm\^3, any white matter lesion that corresponds to an overall Fazekas score of 3 that requires at least one confluent hyperintense lesion on the FLAIR sequence, which is ≥ 20 mm in any dimension
  • Any drop in of > 20% compared to predose on Day 1 or hemoglobin value below 10 g/dL
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    Part 1 (Dose Finding) Cohort 1: Dose Level 1 of RO7126209

    Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.

    Drug: RO7126209

  • Placebo comparator
    Part 1 (Dose Finding) Cohort 1: Placebo

    Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.

    Drug: Placebo

  • Experimental
    Part 1 (Dose Finding) Cohort 2: Dose Level 2 of RO7126209

    Participants will receive multiple doses of RO7126209 at dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: RO7126209

  • Placebo comparator
    Part 1 (Dose Finding) Cohort 2: Placebo

    Participants will receive matching placebo to dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: Placebo

  • Experimental
    Part 1 (Dose Finding) Cohort 3: Dose Level 3 of RO7126209

    Participants will receive multiple doses of RO7126209 at dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: RO7126209

  • Placebo comparator
    Part 1 (Dose Finding) Cohort 3: Placebo

    Participants will receive matching placebo to dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: Placebo

  • Experimental
    Part 1 (Dose Finding) Cohort 4: Dose Level 4 of RO7126209

    Participants will receive multiple doses of RO7126209 at dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: RO7126209

  • Placebo comparator
    Part 1 (Dose Finding) Cohort 4: Placebo

    Participants will receive matching placebo to dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: Placebo

  • Experimental
    Part 1 (Dose Finding) Cohort 5: Dose Level 5 of RO7126209

    Participants will receive a total of 2 doses of RO7126209 at dose level 5 Q4W, for 28 weeks followed by an 8-week safety follow-up period.

    Drug: RO7126209

  • Placebo comparator
    Part 1 (Dose Finding) Cohort 5: Placebo

    Participants will receive a total of 2 doses of matching placebo to dose level 5 Q4W, for 28 weeks followed by an 8-week safety follow-up period.

    Drug: Placebo

  • Experimental
    Part 2 (Expansion) Cohort 1: Dose Level 3 of RO7126209

    Participants will receive multiple doses of RO7126209 at dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: RO7126209

  • Placebo comparator
    Part 2 (Expansion) Cohort 1: Placebo

    Participants will receive matching placebo to dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: Placebo

  • Experimental
    Part 2 (Expansion) Cohort 2: Dose Level 4 of RO7126209

    Participants will receive multiple doses of RO7126209 at dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: RO7126209

  • Placebo comparator
    Part 2 (Expansion) Cohort 2: Placebo

    Participants will receive matching placebo to dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.

    Drug: Placebo

  • Experimental
    Part 2 (Expansion) Cohort 3: Dose Level 5 of RO7126209

    Participants will receive a total of 2 doses of RO7126209 at dose level 5, Q4W, for 28 weeks followed by an 8-week safety follow-up period.

    Drug: RO7126209

  • Placebo comparator
    Part 2 (Expansion) Cohort 3: Placebo

    Participants will receive a total of 2 doses of matching placebo to dose level 5, Q4W, for 28 weeks followed by an 8-week safety follow-up period.

    Drug: Placebo

  • Experimental
    Part 3 (Dose/Frequency/Pharmacodynamic (PD) Relationship): Dose Level 1: RO7126209

    Participants will receive multiple doses of RO7126209 in an open-label treatment period at dose level 1, Q4W, for 24 weeks followed by a 28-week safety follow-up period.

    Drug: RO7126209

  • Experimental
    Part 3 Dose/Frequency/PD Relationship: Dose Level 2: RO7126209

    Participants will receive multiple doses of RO7126209 in an open-label treatment period at dose level 2, Q12W, for 24 weeks followed by a 28-week safety follow-up period.

    Drug: RO7126209

  • Experimental
    Part 4: Open Label Extension (OLE)

    Participants who completed Part 1, 2, or 3 will receive RO7126209 for a maximum of 205 weeks.

    Drug: RO7126209

Interventions

  • RO7126209 will be administered intravenously as specified in each treatment arm.

    Also known as: Trontinemab, RG6102

  • DrugPlacebo

    RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.

    Also known as: RO727-5887, F01-01

06

What researchers measure

Primary outcomes

  1. Part 1, 2, 3, and 4: Percentage of Participants With Adverse Events (AEs)

    Time frame: Part 1 and 2: Up to approximately 56 weeks; Part 3: Up to approximately 52 weeks; Part 4: Up to approximately 233 weeks

  2. Part 3: Change From Baseline in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan

    Time frame: Up to approximately 24 weeks

Secondary outcomes

  1. Part 1, 2, and 4: Change From Baseline in Brain Amyloid Load as Measured by Amyloid PET Scan

    Time frame: Part 1 and 2: Up to approximately 28 weeks; Part 4: Up to approximately 205 weeks

  2. Part 1, 2, 3, and 4: Plasma Concentration of RO7126209

    Time frame: Part 1 and 2: Up to approximately 32 weeks; Part 3: Up to approximately 24 weeks; Part 4: Up to approximately 209 weeks

  3. Part 1, 2, 3, and 4: Cerebral Spinal Fluid (CSF) Concentration of RO7126209

    Time frame: Part 1 and 2: Up to approximately 25 weeks; Part 3: Up to approximately 21 weeks; Part 4: Up to approximately 205 weeks

  4. Part 1, 2, 3, and 4: Number of Participants With Anti-Drug Antibodies (ADAs) to RO7126209

    Time frame: Part 1 and 2: Up to approximately 56 weeks; Part 3: Up to approximately 52 weeks; Part 4: Up to approximately 233 weeks

07

Study locations

37 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Jul 2027, 76 months after the start.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 76 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2020
First posted
Nov 20, 2020
StartActual
Mar 15, 2021
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04639050
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 20, 2020
Start date
Mar 15, 2021
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trontinemab

Start the discussion